Integrated Filing — IndAS



General information about company
Scrip Code 524824
NSE Symbol BALPHARMA
MSEI Symbol NOTLISTED
ISIN INE083D01012
Name of company BAL PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 29-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 15-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment PHARMACEUTICLES
Start date and time of board meeting 29-May-2025   16:30:00
End date and time of board meeting 29-May-2025   17:20:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-13
Indicate Company website link for updated RPT policy of the Company https://www.balpharma.com/balpharmacom/pdf/investors/irl/Policy%20on%20Dealing%20with%20Related%20Party%20Transaction.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The company has not defaulted in repayment of loans during the quarter under review.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 817836000 3024964000
Other income 9910000 21493000
Total income 827746000 3046457000
2 Expenses
(a) Cost of materials consumed 399214000 1498861000
(b) Purchases of stock-in-trade 56662000 149668000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -16439000 -70812000
(d) Employee benefit expense 153490000 618289000
(e) Finance costs 39409000 168451000
(f) Depreciation, depletion and amortisation expense 20684000 96488000
(f) Other Expenses
1 other expenses 146588000 528189000
Total other expenses 146588000 528189000
Total expenses 799608000 2989134000
3 Total profit before exceptional items and tax 28138000 57323000
4 Exceptional items 0 0
5 Total profit before tax 28138000 57323000
6 Tax expense
7 Current tax -11609000 0
8 Deferred tax -16322000 -20672000
9 Total tax expenses -27931000 -20672000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 56069000 77995000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 56069000 77995000
17 Other comprehensive income net of taxes -432000 -432000
18 Total Comprehensive Income for the period 55637000 77563000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 159209000 159209000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 829037000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.51 4.89
Diluted earnings (loss) per share from continuing operations 3.51 4.89
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.51 4.89
Diluted earnings (loss) per share from continuing and discontinued operations 3.51 4.89
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Notes: n n1. The above audited standalone financial results of the company has been reviewed bythe audit committee and approved by the board of directors at their respective meetings held on 29 May 2025. n n2. The standalone financial results has been prepared in accordance with the Companies ( Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting policies to the extend applicable. n n3. The Company has only one reportable segment namely Pharmaceuticals. n n4. The Company has a outstanding recoverability of rs. 869.89 Lakhs and rs. 152.23 lakhs from its subsidiaries Lifezen healthcare Pvt Ltd and Balance Clinics LLP. The said subsidiaries have incurred losses and have a negative networth . However the management is confident that with infusion of additiional funds, introduction of new brands and renewed marketing, internal restructuring, the companies can be revived and the amounts recovered. n n5. the group has not received any intimation or information with regard to its vendor registration as Micro, Small and Medium enterprises. Accordingly, the entire due to vendors has been classified as payable to other than MSME. n n6. Hon'ble NCLT bench Bengaluru passed the order dated 26.03.2025, allowing the merger of Golden Drugs Pvt Ltd with Bal Pharma Limited. n n7. the company has vested 1,16,500 stock options during the year 2024-2025 under Bal Pharma Ltd employees stock option scheme 2014 to its employees. Each stock option is converted into equity shares of Rs. 10 each. n n8. previous period figures have been regrouped / rearranged wherever considered necessary to conform to the period presentation.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 709480000
Capital work-in-progress 27858000
Investment property
Goodwill 38269000
Other intangible assets 119975000
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 21586000
Trade receivables, non-current
Loans, non-current 0
Other non-current financial assets 71224000
Total non-current financial assets 92810000
Deferred tax assets (net) 3953000
Other non-current assets 36774000
Total non-current assets 1029119000
2 Current assets
Inventories 1027780000
Current financial asset
Current investments 24680000
Trade receivables, current 948478000
Cash and cash equivalents 16395000
Bank balance other than cash and cash equivalents 62989000
Loans, current 11328000
Other current financial assets 12763000
Total current financial assets 1076633000
Current tax assets (net) 9884000
Other current assets 362223000
Total current assets 2476520000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 3505639000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 159209000
Other equity 829037000
Total equity attributable to owners of parent 988246000
Non controlling interest
Total equity 988246000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 314003000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities
Total non-current financial liabilities 314003000
Provisions, non-current 56043000
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities 12765000
Total non-current liabilities 382811000
Current liabilities
Current financial liabilities
Borrowings, current 1132114000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 46166000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 772313000
Total Trade payable 818479000
Other current financial liabilities 64858000
Total current financial liabilities 2015451000
Other current liabilities 107515000
Provisions, current 11616000
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 2134582000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 2517393000
Total equity and liabilites 3505639000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 432000 432000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income -432000 -432000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 57323000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 168451000
Adjustments for decrease (increase) in inventories -152438000
Adjustments for decrease (increase) in trade receivables, current 0
Adjustments for decrease (increase) in trade receivables, non-current 67953000
Adjustments for decrease (increase) in other current assets -35180000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current -6497000
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 0
Adjustments for increase (decrease) in trade payables, non-current 43691000
Adjustments for increase (decrease) in other current liabilities -30062000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 96488000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 7922000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 24721000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income -7364000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 2068000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 194481000
Net cash flows from (used in) operations 251804000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 20771000
Other inflows (outflows) of cash -27890000
Net cash flows from (used in) operating activities 203143000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 187699000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 7364000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 31335000
Net cash flows from (used in) investing activities -149000000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 8069000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 107813000
Repayments of borrowings 0
Payments of lease liabilities 0
Dividends paid 19105000
Interest paid 168451000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -6657000
Net cash flows from (used in) financing activities -78331000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -24188000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -24188000
Cash and cash equivalents cash flow statement at beginning of period 40583000
Cash and cash equivalents cash flow statement at end of period 16395000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 SSJNB & Co Yes 31-Mar-2026


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 BAL PHARMA LIMITED Micro Labs Limited Promoter Group Company Any other transaction Revenue from operations. 200000000 omnibus approval given by audit committee on 28.05.2024 32890000 0 0
2 BAL PHARMA LIMITED Lifezen Healthcare Pvt Ltd Subsidiary Company Any other transaction Revenue from operations. 20000000 omnibus approval given by audit committee on 28.05.2024 799000 0 0
3 BAL PHARMA LIMITED Balance Clinics LLP Subsidiary Company Any other transaction Revenue from operations. 30000000 omnibus approval given by audit committee on 28.05.2024 1705000 0 0
4 BAL PHARMA LIMITED Lifezen Healthcare Pvt Ltd Subsidiary Company Any other transaction Rental Income 600000 omnibus approval given by audit committee on 28.05.2024 516000 0 0
5 BAL PHARMA LIMITED Bal Research Foundation Subsidiary Company Any other transaction Rental Income 400000 omnibus approval given by audit committee on 28.05.2024 240000 0 0
6 BAL PHARMA LIMITED Lifezen Healthcare Pvt Ltd Subsidiary Company Purchase of goods or services 10000000 omnibus approval given by audit committee on 28.05.2024 2146000 0 0
7 BAL PHARMA LIMITED Desa Marketing International Proprietory Concern of Director Any other transaction Commission on sales 7134000 omnibus approval given by audit committee on 28.05.2024 7234000 0 0
8 BAL PHARMA LIMITED Shailesh D Siroya Key Managerial Personnel & Promoter Any other transaction Commission on sales 6000000 omnibus approval given by audit committee on 28.05.2024 5135000 0 0
9 BAL PHARMA LIMITED Shailesh D Siroya Key Managerial Personnel & Promoter Any other transaction Rental Expenses 3600000 omnibus approval given by audit committee on 28.05.2024 1500000 0 0
10 BAL PHARMA LIMITED Himesh virupakshya Key Managerial Personnel & Director Remuneration 3713000 omnibus approval given by audit committee on 28.05.2024 3713000 0 0
11 BAL PHARMA LIMITED Abdul Basith Key Managerial Personnel Remuneration 1000000 omnibus approval given by audit committee on 28.05.2024 763000 0 0
12 BAL PHARMA LIMITED Bharath Bhushan Key Managerial Personnel Remuneration 3371000 omnibus approval given by audit committee on 28.05.2024 3371000 0 0
13 BAL PHARMA LIMITED Chittanand Damodar Kotian Key Managerial Personnel & Director. Remuneration 3200000 omnibus approval given by audit committee on 28.05.2024 1481000 0 0
14 BAL PHARMA LIMITED Lifezen Healthcare Pvt Ltd Subsidiary Company Any other transaction Trade Receivables 27316000 nil 27316000 0 0
15 BAL PHARMA LIMITED Balance Clinics LLP Subsidiary Company Any other transaction Trade Receivables 7808000 nil 7808000 0 0
16 BAL PHARMA LIMITED Micro Labs Limited Promoter Group Company Any other transaction Trade Receivables 21558000 nil 21558000 0 0
17 BAL PHARMA LIMITED Bal Research Foundation Subsidiary Company Any other transaction Trade Receivables 1944000 nil 1944000 0 0
18 BAL PHARMA LIMITED Himesh virupakshya Key Mangerial Personnel Loan 0 nil 0 0 0
19 BAL PHARMA LIMITED Lifezen Healthcare Pvt Ltd Subsidiary Company Loan 0 nil 0 0 0
20 BAL PHARMA LIMITED Balance Clinics LLP Subsidiary Company Loan 0 nil 0 0 0
21 BAL PHARMA LIMITED Bal Research Foundation Subsidiary Company Loan 0 nil 0 0 0
22 BAL PHARMA LIMITED Siroya Wellness Proprietory Concern of Director Any other transaction Advances recoverable in cash or kind 98000 nil 98000 0 0
23 BAL PHARMA LIMITED AURUM RESEARCH & ANYLITICAL SOLUTIONS PVT LTD Subsidiary Company Any other transaction Advances recoverable in cash or kind 11000 nil 11000 0 0
24 BAL PHARMA LIMITED Desa Marketing International Proprietory Concern of Director Any other transaction Trade Payables 5394000 nil 5394000 0 0
25 BAL PHARMA LIMITED Lifezen Healthcare Pvt Ltd Subsidiary Company Any other transaction Security Deposit 95300000 nil 95300000 0 0
26 BAL PHARMA LIMITED Balance Clinics LLP Subsidiary Company Any other transaction Advances recoverable in cash or kind 15483000 nil 15483000 0 0
27 BAL PHARMA LIMITED Shailesh D Siroya Key Managerial Personnel Any other transaction Trade Payables 0 nil 0 0 0
28 BAL PHARMA LIMITED Siroya Constructions Proprietory Concern of Director Any other transaction Payable towards capital goods 0 nil 0 0 0
29 BAL PHARMA LIMITED Bal Research Foundation Subsidiary Company Any other transaction Advances recoverable in cash or kind 218000 nil 218000 0 0
30 BAL PHARMA LIMITED Lifezen Healthcare Pvt Ltd Subsidiary Company Any other transaction Other Cuurent Assets 0 nil 0 0 0
31 BAL PHARMA LIMITED Siroya Constructions Proprietory Concern of Director Any other transaction Trade Payables 144000 nil 144000 0 0
32 BAL PHARMA LIMITED Himesh virupakshya Key managerial Personnel Any other transaction Other Cuurent Assets 25000 nil 25000 0 0
33 BAL PHARMA LIMITED Shailesh D Siroya Key managerial Personnel Any other transaction Remuneration 18333000 omnibus approval given by audit committee on 28.05.2024 18333000 0 0
34 BAL PHARMA LIMITED Siroya properyties and holdings private limited Entity in which Key Manageriak personnal has interest in Any other transaction Capital advances 7451000 nil 7451000 0 0
35 BAL PHARMA LIMITED Balance Clinics LLP Subsidiary Company Any other transaction Trade Payables 953000 nil 953000 0 0
36 BAL PHARMA LIMITED Bal Research Foundation Subsidiary Company Any other transaction rental deposits 100000 nil 100000 0 0
37 BAL PHARMA LIMITED Lifezen Healthcare Pvt Ltd Subsidiary Company Any other transaction rental deposits 300000 nil 300000 0 0
38 BAL PHARMA LIMITED Shailesh D Siroya Key managerial personnal Any other transaction other current liabilities 5893000 nil 5893000 0 0
Total value of transaction during the reporting period 269822000